Invitation to the annual shareholders’ meeting
08 avr. 2024 09h17 HE
|
Novozymes A/S
The annual shareholders’ meeting will be held on Tuesday April 30, 2024 at 4:00 pm CET at Bella Center, Center Boulevard 5, Denmark. The distribution of profit will be addressed at the meeting and...
Share-based legacy RSU program granted
08 avr. 2024 05h58 HE
|
Novozymes A/S
Share-based legacy RSU program granted Novonesis’ Board of Directors has following the merger with Chr. Hansen Holding A/S (“Chr. Hansen”) today approved the continuation in 2024 of a...
2024 outlook and pro forma financials
21 mars 2024 02h26 HE
|
Novozymes A/S
Novonesis provides outlook for 2024 with expected 5-7% organic sales growth and ~35% adj. EBITDA margin. Pro forma financials disclosed. Ester Baiget, CEO of Novonesis, said: “Today we provide...
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21
18 mars 2024 10h26 HE
|
Novozymes A/S
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 at 9.00am CET. To join the live webcast, please click here. To register and receive access...
Resolutions from the Extraordinary Shareholders’ Meeting 2024
04 mars 2024 11h06 HE
|
Novozymes A/S
Company Announcement no. 10 March 4, 2024Today an extraordinary shareholders’ meeting was conducted. The following resolutions were made: Adoption of Novonesis A/S as secondary name and...
Invitation to an extraordinary shareholders’ meeting of Novozymes A/S
09 févr. 2024 04h00 HE
|
Novozymes A/S
An extraordinary shareholders’ meeting of Novozymes A/S will be held on Monday March 4, 2024 at 4:00 pm CET at Boege Alle 10-12, 2970 Hoersholm, Denmark.
Attachments
...
The Novozymes Report 2023
08 févr. 2024 13h52 HE
|
Novozymes A/S
This annual report has been released subsequent to the approval of the combination of Novozymes and Chr. Hansen on January 29, 2024. The new combined group is called Novonesis. As an annual...
Trading by management and close relations of management
02 févr. 2024 08h13 HE
|
Novozymes A/S
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and...
Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed
02 févr. 2024 02h28 HE
|
Novozymes A/S
Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed February 2, 2024Company announcement No. 07 On January 29, 2024, following the satisfaction of...
Legacy Novozymes delivers solid last full-year results
01 févr. 2024 02h00 HE
|
Novozymes A/S
Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks...